USPTO serial 79344258
METEOR
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- MURRAY, DAVID T
- Law office
- TMO LAW OFFICE 113
What this means
These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.
Need help with METEOR?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Karl M. Zielaznicki, Esq.
Karl M. Zielaznicki, Esq. Troutman Pepper Hamilton Sanders LLP875 Third Avenuec/o IP Services NYCNew York, NY 10022Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | biological preparations for use in industry and science; biological substances, biological materials and biological preparations, and natural elements, namely proteins, peptide substrates, monoclonal antibodies, DNA, RNA, mRNA, cells and viruses for scientific, laboratory, medical and medical research use; biological preparations for use in science; monoclonal antibodies for scientific purposes, other than for medical or veterinary use; antibody reagents for scientific purposes; tagged monoclonal antibodies and multi-specific antibodies for scientific use; tagged monoclonal antibodies and multi-specific antibodies for laboratory use; proteins for binding antibodies and multi-specific antibodies for scientific, laboratory, medical and medical research use; proteins for detecting antibodies and multi-specific antibodies for scientific, laboratory, medical and medical research use; biochemical precursors for scientific purposes, namely, precursors for scientific, laboratory, medical and medical research use; biochemical preparations for scientific purposes, namely, precursors for scientific, laboratory, medical and medical research; biochemical reagents used for non-medical purposes; chemical substances, chemical materials and chemical preparations, and natural elements, namely proteins, peptides substrates, monoclonal antibodies, DNA, RNA, mRNA, cells and viruses in relation to antibodies and multi-specific antibodies for scientific, laboratory or medical research use; biological substances, biological materials and biological preparations, and natural elements, namely proteins, peptide substrates, monoclonal antibodies, DNA, RNA, mRNA, cells and viruses in relation to antibodies and multi-specific antibodies for scientific, laboratory, medical and medical research use; chemical substances, chemical materials and chemical preparations, and natural elements, namely proteins, peptide substrates, monoclonal antibodies, DNA, RNA, mRNA, cells and viruses in relation to immunohistochemistry (IHC) and flow cytometry for scientific, laboratory, medical and medical research use; biological substances, biological materials and biological preparations, and natural elements, namely proteins, peptide substrates, monoclonal antibodies, DNA, RNA, mRNA, cells and viruses in relation to immunohistochemistry (IHC) and flow cytometry for scientific, laboratory, medical and medical research use; chemical substances, chemical materials and chemical preparations, and natural elements, namely proteins, peptide substrates, monoclonal antibodies, DNA, RNA, mRNA, cells and viruses in relation to gamma delta t cells for scientific, laboratory, medical and medical research use; biological substances, biological materials and biological preparations, and natural elements, namely proteins, peptide substrates, monoclonal antibodies, DNA, RNA, mRNA, cells and viruses in relation to gamma delta t cells for scientific, laboratory, medical and medical research use; chemical substances, chemical materials and chemical preparations, and natural elements, namely proteins, peptide substrates, monoclonal antibodies, DNA, RNA, mRNA, cells and viruses in relation to immunohistochemistry (IHC) and flow cytometry for scientific, laboratory, medical and medical research use; biological substances, biological materials and biological preparations, and natural elements, namely proteins, peptides substrates, monoclonal antibodies, DNA, RNA, mRNA, cells and viruses in relation to immunohistochemistry (IHC) and flow cytometry for scientific, laboratory, medical and medical research use; chemical compositions and preparations for use in science in relation to antibodies and multispecific antibodies; chemical compositions and preparations for use in science in relation to gamma delta t cells; chemical compositions and preparations for use in science in relation to immunohistochemistry (IHC) and flow cytometry; chemical compositions and preparations for use in science in relation to immunohistochemistry (IHC) and flow cytometry; biological compositions and preparations for use in science in relation to antibodies and multi-specific antibodies; biological compositions and preparations for use in science in relation to gamma delta t cells; biological compositions and preparations for use in science in relation to immunohistochemistry (IHC) and flow cytometry; biological compositions and preparations for use in science in relation to immunohistochemistry (IHC) and flow cytometry; biochemical and biological precursors for scientific purposes in relation to antibodies and multi-specific antibodies; biochemical and biological precursors for scientific purposes in relation to gamma delta t cells; biochemical and biological precursors for scientific purposes in relation to immunohistochemistry (IHC) and flow cytometry; biochemical and biological precursors for scientific purposes in relation to immunohistochemistry (IHC) and flow cytometry; biochemical and biological preparations for scientific purposes in relation to antibodies and multi-specific antibodies; biochemical and biological preparations for scientific purposes in relation to gamma delta t cells; biochemical and biological preparations for scientific purposes in relation to immunohistochemistry (IHC) and flow cytometry; biochemical and biological preparations for scientific purposes in relation to immunohistochemistry (IHC) and flow cytometry; biochemical and biological reagents used for non-medical purposes in relation to antibodies and multi-specific antibodies; biochemical and biological reagents used for non-medical purposes in relation to gamma delta t cells; biochemical and biological reagents used for non-medical purposes in relation to immunohistochemistry (IHC) and flow cytometry; biochemical and biological reagents used for non-medical purposes in relation to immunohistochemistry (IHC) and flow cytometry; none of the aforesaid goods in relation to agriculture, horticulture or forestry or assays for research purposes | ACTIVE | — |
| 005 | Pharmaceuticals, namely, pharmaceutical preparations for the prevention and treatment of human disorders or diseases; antibodies and multi-specific antibodies, namely, colostral antibodies for medical purposes; biotechnological preparations for medical use; capsules sold empty for pharmaceuticals; drug delivery agents in the form of capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; drugs for medical purposes, namely, pharmaceutical products for the prevention and treatment of cancer; injectable pharmaceuticals, namely, pharmaceutical products for the prevention and treatment of cancer; medical preparations and articles, namely, pharmaceutical products for the prevention and treatment of cancer; medicines for human purposes, namely, pharmaceutical products for the prevention and treatment of cancer; pharmaceutical compositions namely, pharmaceutical products for the prevention and treatment of cancer; pharmaceutical drugs namely, pharmaceutical products for the prevention and treatment of cancer; pharmaceutical preparations namely, pharmaceutical products for the prevention and treatment of cancer; pharmaceutical preparations and substances namely, pharmaceutical products for the prevention and treatment of cancer; pharmaceutical preparations for activating cellular function; pharmaceutical preparations for human use namely, pharmaceutical products for the prevention and treatment of cancer; pharmaceutical preparations for immunity adjustment; pharmaceutical preparations for medical purposes namely, pharmaceutical products for the prevention and treatment of cancer; pharmaceutical preparations for regulating the immune system; pharmaceutical preparations for the prevention of autoimmune diseases; pharmaceutical preparations for the prevention of autoimmune disorders; pharmaceutical preparations for the treatment of autoimmune diseases; pharmaceutical preparations for the treatment of autoimmune disorders; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of viral diseases; pharmaceutical preparations for the treatment of anti-infective diseases; pharmaceutical preparations for the treatment of infectious diseases and for use in oncology; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of viral diseases; pharmaceutical preparations for the treatment of anti-infective diseases; pharmaceuticals preparations namely, pharmaceutical products for the prevention and treatment of cancer; biotechnological preparations for medical use in relation to antibodies and multi-specific antibodies for treating human diseases and disorders; biotechnological preparations for medical use in relation to gamma delta t cells; biotechnological preparations for medical use in relation to immunohistochemistry (IHC) and flow cytometry antibodies for treating human diseases and disorders; chemical preparations for pharmaceutical purposes in relation to antibodies and multi- specific antibodies for treating human diseases and disorders; chemical preparations for pharmaceutical purposes in relation to gamma delta t cells antibodies for treating human diseases and disorders; chemical preparations for pharmaceutical purposes in relation to immunohistochemistry (IHC) and flow cytometry antibodies for treating human diseases and disorders; chemicals for pharmaceutical use in relation to antibodies and multispecific antibodies for treating human diseases and disorders; chemicals for pharmaceutical use in relation to gamma delta t cells antibodies for treating human diseases and disorders; chemicals for pharmaceutical use in relation to immunohistochemistry (IHC) and flow cytometry antibodies for treating human diseases and disorders; drug delivery agents for controlled release of the active ingredients for a wide variety of pharmaceuticals in relation to antibodies and multi-specific antibodies; drug delivery agents in the form of capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals in relation to gamma delta t cells; drug delivery agents in the form of capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals in relation to immunohistochemistry (IHC) and flow cytometry; drugs for medical purposes in relation to antibodies and multi-specific antibodies for treating human diseases and disorders; drugs for medical purposes in relation to gamma delta t cells for treating human diseases and disorders; drugs for medical purposes in relation to immunohistochemistry (IHC) and flow cytometry for treating human diseases and disorders; pharmaceutical preparations in relation to antibodies and multi-specific antibodies for treating human diseases and disorders; pharmaceutical preparations in relation to gamma delta t cells for treating human diseases and disorders; pharmaceutical preparations in relation to immunohistochemistry (IHC) and flow cytometry for treating human diseases and disorders; pharmaceutical preparations in relation to antibodies and multi-specific antibodies for treating human diseases and disorders; pharmaceutical preparations in relation to gamma delta t cells for treating human diseases and disorders; pharmaceutical preparations in relation to immunohistochemistry (IHC) and flow cytometry for treating human diseases and disorders; pharmaceuticals in relation to antibodies and multispecific antibodies for treating human diseases and disorders; pharmaceuticals in relation to gamma delta t cells for treating human diseases and disorders; pharmaceuticals in relation to immunohistochemistry (IHC) and flow cytometry for treating human diseases and disorders; none of the aforesaid goods in relation to agriculture, horticulture or forestry | ACTIVE | — |
| 042 | biological research; clinical research in the field of pharmaceuticals; medical research; biomedical research services; clinical trials, namely, scientific research in the nature of conducting clinical trials for others; conducting scientific clinical trials for pharmaceutical products for others; conducting early evaluations in the field of new pharmaceuticals; consultancy in the field of pharmaceutical research; consultancy relating to pharmaceutical research and development; development of pharmaceutical preparations and medicines; drug discovery services; information technology services for the pharmaceutical and healthcare industries; inspection of pharmaceuticals; laboratory research services relating to pharmaceuticals; medical and pharmacological research services; pharmaceutical drug development services; pharmaceutical product evaluation; pharmaceutical products development; pharmaceutical research and development; pharmaceutical research and development services; pharmaceutical research services; providing information about the results of clinical trials for pharmaceutical products; research and development in the pharmaceutical and biotechnology fields; research and development of vaccines and medicines; research and development services in the field of antibodies and multi-specific antibodies; research and development services in the field of antibody technology; scientific research relating to medicines; research and development in the field of medical diagnostic preparations; biological research, clinical research and medical research in relation to antibodies and multi-specific antibodies; biological research, clinical research and medical research in relation to gamma delta t cells; biological research, clinical research and medical research in relation to immunohistochemistry (IHC) and flow cytometry; consultancy relating to pharmaceutical research and development in relation to antibodies and multi-specific antibodies; consultancy relating to pharmaceutical research and development in relation to gamma delta t cells; consultancy relating to pharmaceutical research and development in relation to immunohistochemistry (IHC) and flow cytometry; laboratory research services relating to pharmaceuticals in relation to antibodies and multi-specific antibodies; laboratory research services relating to pharmaceuticals in relation to gamma delta t cells; laboratory research services relating to pharmaceuticals in relation to immunohistochemistry (IHC) and flow cytometry; medical and pharmacological research services in relation to antibodies and multi-specific antibodies; medical and pharmacological research services in relation to gamma delta t cells; medical and pharmacological research services in relation to immunohistochemistry (IHC) and flow cytometry; pharmaceutical research and development services in relation to antibodies and multi-specific antibodies; pharmaceutical research and development services in relation to gamma delta t cells; pharmaceutical research and development services in relation to immunohistochemistry (IHC) and flow cytometry; scientific and technological services in relation to scientific research in the field of antibodies and multi-specific antibodies; scientific and technological services in relation scientific research in the field of gamma delta t cells; scientific and technological services in relation scientific research in the field of immunohistochemistry (IHC) and flow cytometry; scientific research and development in relation to antibodies and multi-specific antibodies; scientific research and development in relation to gamma delta t cells; scientific research and development in relation to immunohistochemistry (IHC) and flow cytometry; information, advisory and consultancy services relating the aforesaid services, and none of the aforesaid services in relation to agriculture, horticulture or forestry | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Adaptate Biotherapeutics Limited
- Other trademarks owned by GammaDelta Therapeutics Ltd
- Other trademarks owned by GammaDelta Therapeutics Ltd
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 042
- Similar marks named METEOR
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 6, 2026 | FINT | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Jul 20, 2026 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Jul 18, 2026 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Jul 18, 2025 | MAB2 | ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Jul 18, 2025 | ABN2 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Feb 28, 2025 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Jan 3, 2025 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 3, 2025 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 3, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 25, 2024 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| May 31, 2024 | ADCH | CHANGE OF NAME/ADDRESS REC'D FROM IB | — |
| Apr 16, 2024 | RCSC | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | — |
| Jan 2, 2024 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Dec 13, 2023 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Dec 13, 2023 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Oct 18, 2023 | RCSC | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | — |
| Apr 20, 2023 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Apr 20, 2023 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Apr 20, 2023 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Mar 30, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 29, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 29, 2023 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 4, 2023 | CHLD | CHANGE OF OWNER RECEIVED FROM IB | — |
| Oct 26, 2022 | RFNT | REFUSAL PROCESSED BY IB | — |
| Sep 30, 2022 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Sep 30, 2022 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Aug 24, 2022 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Aug 23, 2022 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 19, 2022 | DOCK | ASSIGNED TO EXAMINER | — |
| Jul 12, 2022 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jul 8, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jul 7, 2022 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |